Work

A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab in metastatic pancreatic cancer (PanCa)

Year: 2006

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2006.24.18_suppl.4041

Authors: A. H. Ko, E. Dito, B. Schillinger, R. Hajnal, A. P. Venook, E. K. Bergsland, J. Allen, S. Rajpal, M. A. Tempero

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2562671453

Cites:

Cited by: 2

Related to: 10